'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech
ANI
Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial...
Krishna Ella
News and Video Search Results
News coverage
India's vaccination drive against Covid-19
BBC World News - Affiliate
'Who will opt for vaccine...': Congress questions approval, slams govt
HT Digital Content
- More about:
Covaxin- Manish Tewari
- Krishna Ella
- Bharat Biotech
- Hyderabad
0 shares
1 views
You might like
Krishna Ella media coverage
COVAXIN is vaccine, not backup: Bharat Biotech MD
ANI
While addressing a press conference via video conferencing in Hyderabad on January 04, the Chairman and Managing Director (MD) of..
Advertisement
More coverage
COVAXIN has shown less than 10% adverse reactions: Bharat Biotech MD
ANI
While addressing a press conference via video conferencing in Hyderabad on January 04, the Chairman and Managing Director (MD) of..
